The OD’s role with new diabetes drugsIt is important for eyecare providers to be familiar with these new drugs and findings. We often see patients with diabetes, metabolic syndrome, and high CV risk, and we are in a position to help counsel our patients about new treatments—and even suggest that appropriate patients have conversations with their primary-care physicians, endocrinologists and cardiologists.
New diabetes drug set to rival TrulicityIf it is approved by FDA, an investigational drug to improve glycemic control in patients with type 2 diabetes will likely be a strong competitor to Eli Lilly’s dulaglutide (Trulicity).
New diabetes drug up against leading brandsFDA approved lixisenatide (Adlyxin, Sanofi-Aventis), a once-daily mealtime GLP-1 receptor agonist injection for type 2 diabetes, which will compete against the once-weekly pen dulaglutide (Trulicity, Eli Lilly) and the injectable liraglutide (Victoza, Novo Nordisk).
GLP-1 receptor more beneficial in reducing blood sugar compared to injectable therapy in Japanese patientsOnce-weekly dulaglutide is an effective treatment option for patients with type 2 diabetes who need to advance to injectable therapy, according to results from a Japanese study presented at the 2015 American Diabetes Association Scientific Sessions in Boston
New type 2 diabetes drug approved by FDAFDA has approved Trulicity (dulaglutide, Eli Lilly) to treat type 2 diabetes mellitus.
FDA approves once-weekly GLP-1 receptor agonist for type 2 diabetesFDA has approved dulaglutide (Trulicity, Eli Lilly) to treat type 2 diabetes mellitus. The drug is a once-weekly subcutaneous injection used to improve glycemic control and is indicated as an adjunct to diet and exercise in the management of type 2 diabetes in adults.
FDA drug approvals-September 2014FDA actions in brief, fast-track designations,priority review, orphan drug designations